Skip to main content

Published locations for HR+/HER2− metastatic BC: No survival benefit with palbociclib+ET over capecitabine in patients who progress on AI therapy

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. HR+/HER2− metastatic BC: No survival benefit with palbociclib+ET over capecitabine in patients who progress on AI therapy

User login

  • Reset your password
  • /content/hr/her2-metastatic-bc-no-survival-benefit-palbociclibet-over-capecitabine-patients-who
  • /hematology-oncology/article/254750/breast-cancer/hr/her2-metastatic-bc-no-survival-benefit
  • /breast-cancer-icymi/article/254750/breast-cancer/hr/her2-metastatic-bc-no-survival-benefit